Kezar Life Sciences KZR 深 滬
等待開盤 10-31 09:30:00 美东时间
6.23
+0.080
+1.30%
華盛通- 最 高6.27
- 今 開6.21
- 成交量 9.37万股
- 最 低 6.15
- 昨 收 6.15
- 總市值 4562.29万
- 52周最高 7.65
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.5334
- 委 比 91.20%
- 總股本 732.31万
- 歷史最高 363.27
- 量 比 0.92
- 振 幅 1.95%
- 歷史最低 3.5334
- 每 手 1
- 風險率 1.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kezar Life Sciences Repays Loan, Ends Agreement
The latest update is out from Kezar Life Sciences ( ($KZR) ). On October 20, 20...
10-23 04:53
美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
快讯 | 凯泽生命科学公司：杰富瑞将评级从买入下调至持有；目标价从18美元下调至7美元
Kezar Life Sciences Inc : Jefferies Cuts to Hold From Buy; Cuts Target Price to...
10-17 11:47
Kezar Life Sciences Initiates Strategic Alternatives Review, Announces Workforce Restructuring And Rights Plan Extension After FDA Blocks Path Forward For Zetomipzomib In Autoimmune Hepatitis; Reports $90.2M Cash Balance
Kezar Life Sciences, Inc. (NASDAQ:KZR, the Company))), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced regulatory
10-17 04:09
快讯 | Kezar生命科学公司：缺乏资源延长Zetomipzomib的开发时间表
Kezar Life Sciences Inc: Lack Resources to Extend Development Timeline for Zeto...
10-17 04:09
快讯 | Kezar生命科学公司 - 延长股东权益计划的期限
Kezar Life Sciences Inc - Extends Duration of Stockholder Rights Plan
10-17 04:08
Kalamazoo Resources Schedules General Meeting for Shareholder Resolutions
The latest announcement is out from Kalamazoo Resources Ltd. ( ($AU:KZR) ). Kal...
08-26 15:28
Kezar Life Sciences Advances in Autoimmune Hepatitis Trials
Kezar Life Sciences ( ($KZR) ) has released its Q2 earnings. Here is a breakdow...
08-14 12:31
Kalamazoo Resources Ltd. Announces Trading Halt Pending Acquisition News
An announcement from Kalamazoo Resources Ltd. ( ($AU:KZR) ) is now available. K...
07-25 08:29
Kezar Life Sciences Announces FDA Lifted Partial Clinical Hold On Phase 2a Trial Of Zetomipzomib For Autoimmune Hepatitis
Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of
07-16 04:41
